- Home
- KD vs CORT Comparison
KD vs CORT Comparison
Compare KD & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KD
- CORT
- Stock Information
- Founded
- KD 2020
- CORT 1998
- Country
- KD United States
- CORT United States
- Employees
- KD N/A
- CORT N/A
- Industry
- KD EDP Services
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- KD Technology
- CORT Health Care
- Exchange
- KD Nasdaq
- CORT Nasdaq
- Market Cap
- KD 7.0B
- CORT 7.6B
- IPO Year
- KD N/A
- CORT N/A
- Fundamental
- Price
- KD $31.18
- CORT $68.82
- Analyst Decision
- KD Strong Buy
- CORT Strong Buy
- Analyst Count
- KD 3
- CORT 4
- Target Price
- KD $46.00
- CORT $138.25
- AVG Volume (30 Days)
- KD 3.6M
- CORT 825.0K
- Earning Date
- KD 08-04-2025
- CORT 07-31-2025
- Dividend Yield
- KD N/A
- CORT N/A
- EPS Growth
- KD N/A
- CORT N/A
- EPS
- KD 1.23
- CORT 1.11
- Revenue
- KD $15,061,000,000.00
- CORT $716,080,000.00
- Revenue This Year
- KD $5.89
- CORT $35.85
- Revenue Next Year
- KD $2.58
- CORT $35.22
- P/E Ratio
- KD $25.41
- CORT $62.21
- Revenue Growth
- KD N/A
- CORT 25.71
- 52 Week Low
- KD $22.26
- CORT $33.34
- 52 Week High
- KD $44.20
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- KD 38.61
- CORT 42.33
- Support Level
- KD $29.85
- CORT $70.05
- Resistance Level
- KD $31.44
- CORT $71.28
- Average True Range (ATR)
- KD 0.95
- CORT 1.78
- MACD
- KD 0.30
- CORT -0.21
- Stochastic Oscillator
- KD 88.75
- CORT 0.78
About KD Kyndryl Holdings Inc.
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.